Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AL5424 is a synthetic small molecule compound belonging to the class of organic compounds known as sulfanilides. It has been studied in the context of drug discovery and development and is structurally characterized as (4R)-4-hydroxy-2-(4-methoxyphenyl)-1,1-dioxo-3H,4H-1λ6,7,2-thieno[3,2-e][1λ6,2]thiazine-6-sulfonamide. The mechanism of action for AL5424 involves inhibition of carbonic anhydrase II (CA-II), an enzyme that catalyzes the reversible hydration of carbon dioxide and plays a role in fluid secretion regulation in tissues such as the eye. Inhibition of CA-II is relevant for conditions like glaucoma and other diseases where modulation of fluid balance or acid-base homeostasis is therapeutic[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AL5424.